-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Private Advisor Group LLC Purchases 776 Shares of PerkinElmer, Inc. (NYSE:PKI)
Private Advisor Group LLC Purchases 776 Shares of PerkinElmer, Inc. (NYSE:PKI)
Private Advisor Group LLC lifted its position in PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 23.0% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,156 shares of the medical research company's stock after purchasing an additional 776 shares during the quarter. Private Advisor Group LLC's holdings in PerkinElmer were worth $591,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in PKI. Sumitomo Mitsui DS Asset Management Company Ltd grew its holdings in PerkinElmer by 20.9% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 8,267 shares of the medical research company's stock worth $1,176,000 after acquiring an additional 1,430 shares during the last quarter. Wedmont Private Capital grew its holdings in PerkinElmer by 48.1% during the 2nd quarter. Wedmont Private Capital now owns 2,481 shares of the medical research company's stock worth $353,000 after acquiring an additional 806 shares during the last quarter. DnB Asset Management AS grew its holdings in PerkinElmer by 8.7% during the 2nd quarter. DnB Asset Management AS now owns 25,482 shares of the medical research company's stock worth $3,624,000 after acquiring an additional 2,033 shares during the last quarter. Moody National Bank Trust Division acquired a new position in PerkinElmer during the 2nd quarter valued at about $208,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in PerkinElmer by 14.3% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,704 shares of the medical research company's stock valued at $5,008,000 after purchasing an additional 3,595 shares during the period. Institutional investors own 77.06% of the company's stock.
Get PerkinElmer alerts:Insider Transactions at PerkinElmer
In other news, insider Daniel R. Tereau sold 5,700 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the transaction, the insider now directly owns 13,380 shares of the company's stock, valued at approximately $1,941,973.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Daniel R. Tereau sold 5,700 shares of the firm's stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $145.14, for a total transaction of $827,298.00. Following the completion of the transaction, the insider now directly owns 13,380 shares of the company's stock, valued at approximately $1,941,973.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Andrew Okun sold 3,173 shares of the firm's stock in a transaction on Monday, August 1st. The shares were sold at an average price of $165.42, for a total transaction of $524,877.66. Following the completion of the transaction, the insider now directly owns 6,391 shares of the company's stock, valued at $1,057,199.22. The disclosure for this sale can be found here. Company insiders own 0.52% of the company's stock.
PerkinElmer Stock Performance
Shares of PKI stock opened at $131.35 on Thursday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 2.02. The company has a market capitalization of $16.58 billion, a P/E ratio of 24.60, a price-to-earnings-growth ratio of 0.34 and a beta of 1.15. The company's 50 day moving average price is $139.53 and its two-hundred day moving average price is $147.12. PerkinElmer, Inc. has a 52 week low of $116.18 and a 52 week high of $203.16.PerkinElmer (NYSE:PKI – Get Rating) last announced its earnings results on Monday, August 1st. The medical research company reported $2.32 EPS for the quarter, topping the consensus estimate of $2.03 by $0.29. The firm had revenue of $1.23 billion for the quarter, compared to the consensus estimate of $1.20 billion. PerkinElmer had a net margin of 13.21% and a return on equity of 16.68%. The business's quarterly revenue was up .1% on a year-over-year basis. During the same period last year, the company posted $2.83 EPS. On average, analysts expect that PerkinElmer, Inc. will post 7.83 earnings per share for the current fiscal year.
PerkinElmer Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 11th. Stockholders of record on Friday, October 21st will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, October 20th. This represents a $0.28 annualized dividend and a dividend yield of 0.21%. PerkinElmer's dividend payout ratio is currently 5.24%.
Wall Street Analysts Forecast Growth
PKI has been the topic of a number of research reports. Stifel Nicolaus downgraded shares of PerkinElmer from a "buy" rating to a "hold" rating and cut their target price for the company from $190.00 to $170.00 in a research report on Thursday, August 18th. Robert W. Baird upped their target price on shares of PerkinElmer from $198.00 to $202.00 and gave the company an "outperform" rating in a research report on Tuesday, August 2nd. The Goldman Sachs Group cut their target price on shares of PerkinElmer from $200.00 to $175.00 and set a "neutral" rating on the stock in a research report on Thursday, July 14th. Barclays cut their price target on shares of PerkinElmer from $149.00 to $140.00 and set an "underweight" rating on the stock in a research report on Monday, September 12th. Finally, TheStreet downgraded shares of PerkinElmer from a "b" rating to a "c+" rating in a research report on Friday, September 23rd. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, PerkinElmer has a consensus rating of "Hold" and a consensus price target of $162.50.
PerkinElmer Profile
(Get Rating)
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.
Featured Stories
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- 3 Alzheimer Stocks to Buy as the Race for a Cure Heats Up
- Don't Forget About These Cheap, Fundamentally Strong Tech Stocks
- Bellwether RPM International Pops On Results
- Rivian Checks Off Boxes, But Still Needs a Lot to Go Right
- Hot Potato: Lamb Weston Stock Confirms a Top
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
根据最近提交给美国证券交易委员会的文件,Private Advisor Group LLC在第二季度将其在PerkinElmer,Inc.(纽约证券交易所代码:PKI-GET)的持仓上调了23.0%。该基金在本季度额外购买了776股后,持有这家医学研究公司的4,156股股票。在最近一次报告期结束时,Private Advisor Group LLC持有的PerkinElmer股份价值591,000美元。
其他几家大型投资者也改变了他们在PKI中的头寸。三井住友DS资产管理有限公司第二季度增持PerkinElmer股份20.9%。三井住友DS资产管理有限公司在上个季度增持了1,430股后,现在拥有这家医疗研究公司8,267股股票,价值1,176,000美元。韦德蒙私人资本在第二季度增持了48.1%的PerkinElmer股份。韦德蒙私人资本公司现在拥有这家医学研究公司2481股股票,价值35.3万美元,在上个季度又购买了806股。DNB Asset Management AS在第二季度增持了8.7%的PerkinElmer股份。DNB Asset Management AS现在拥有这家医疗研究公司25,482股股票,价值3,624,000美元,此前在上个季度又购买了2,033股。穆迪国家银行信托部门在第二季度收购了PerkinElmer的一个新头寸,价值约20.8万美元。最后,未来资产全球投资有限公司在第一季度将其在PerkinElmer的头寸提高了14.3%。未来资产全球投资有限公司现在拥有28,704股这家医疗研究公司的股票,价值5,008,000美元,在此期间又购买了3,595股。机构投资者持有该公司77.06%的股份。
到达PerkinElmer警报:PerkinElmer的内幕交易
在其他新闻方面,内部人士Daniel·R·特罗在7月22日星期五的一笔交易中出售了5,700股该公司的股票。这些股票以145.14美元的平均价格出售,总成交金额为827,298.00美元。交易完成后,这位内部人士现在直接持有该公司13,380股股票,价值约1,941,973.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。在其他新闻方面,内部人士Daniel·R·特罗在7月22日星期五的一笔交易中出售了5,700股该公司的股票。这些股票以145.14美元的平均价格出售,总成交金额为827,298.00美元。交易完成后,这位内部人士现在直接持有该公司13,380股股票,价值约1,941,973.20美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可通过此超链接。此外,内部人士安德鲁·奥肯在8月1日星期一的一次交易中出售了3173股该公司的股票。这些股票以165.42美元的平均价格出售,总成交金额为524,877.66美元。交易完成后,该内部人士现在直接持有该公司6,391股股票,价值1,057,199.22美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司0.52%的股份。
PerkinElmer股票表现
周四,PKI股票开盘报131.35美元。该公司的负债权益比率为0.63,速动比率为1.42,流动比率为2.02。该公司市值为165.8亿美元,市盈率为24.60倍,市盈率为0.34倍,贝塔系数为1.15。该公司的50日移动均线价格为139.53美元,200日移动均线价格为147.12美元。PerkinElmer,Inc.的52周低点为116.18美元,52周高位为203.16美元。PerkinElmer(纽约证券交易所代码:PKI-GET Rating)上一次公布收益结果是在8月1日星期一。这家医疗研究公司公布本季度每股收益为2.32美元,比普遍预期的2.03美元高出0.29美元。该公司本季度营收为12.3亿美元,而市场普遍预期为12.亿美元。PerkinElmer的净利润率为13.21%,股本回报率为16.68%。该业务的季度收入同比增长了1.1%。去年同期,该公司公布的每股收益为2.83美元。分析师平均预计,PerkinElmer,Inc.本财年每股收益将达到7.83美元。
PerkinElmer宣布派息
该公司最近还宣布了季度股息,将于11月11日星期五支付。10月21日(星期五)登记在册的股东将获得每股0.07美元的股息。除息日期为10月20日星期四。这意味着年化股息为0.28美元,股息收益率为0.21%。PerkinElmer的派息比率目前为5.24%。
华尔街分析师预测经济增长
公钥基础设施已经成为许多研究报告的主题。Stifel Nicolaus在8月18日周四的一份研究报告中将PerkinElmer的股票评级从买入下调至持有,并将该公司的目标价从190.00美元下调至170.00美元。8月2日,罗伯特·W·贝尔德在一份研究报告中将PerkinElmer的股票目标价从198.00美元上调至202.00美元,并给予该公司“跑赢大盘”的评级。7月14日,高盛夫妇在一份研究报告中将PerkinElmer的股票目标价从200.00美元下调至175.00美元,并将其股票评级定为“中性”。巴克莱将PerkinElmer的股票目标价从149.00美元下调至140.00美元,并在9月12日周一的一份研究报告中将该股的评级定为“减持”。最后,华尔街在9月23日星期五的一份研究报告中将PerkinElmer的股票评级从“b”下调至“c+”。一名股票研究分析师将该股评级为卖出,5名分析师给予持有评级,4名分析师对该股给予买入评级。根据MarketBeat.com的数据,PerkinElmer的共识评级为持有,共识目标价为162.50美元。
PerkinElmer配置文件
(获取评级)
PerkinElmer,Inc.为全球诊断、生命科学和应用服务市场提供产品、服务和解决方案。它通过两个部门运行:发现和分析解决方案以及诊断。发现与分析解决方案部门提供一整套解决方案,包括试剂、信息学、检测和成像技术,使科学家能够加强生命科学研究市场的研究突破,以及合同研究和实验室服务。
专题报道
- 免费获取StockNews.com关于PerkinElmer的研究报告(PKI)
- 随着治疗竞赛升温,3只阿尔茨海默病股票将被买入
- 不要忘记这些廉价的、从根本上强劲的科技股
- 领头羊RPM国际流行业绩
- Rivian打掉了包袱,但仍有很多事情要做
- 辣土豆:韦斯顿羊肉库存涨幅居前
接受PerkinElmer Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PerkinElmer和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧